NCT02390635RecruitingPhase 1
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
PET/MR, PET/CT and Whole Body MR in Newly Diagnosed Acute Myeloid Leukemia (AML)
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and whole body MRI work in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia. Extramedullary myeloid leukemia is a type of cancer found outside of the bone marrow and can be hard to detect with routine bone marrow monitoring, such as bone marrow aspirations. Diagnostic procedures, such as PET/MRI, 18F-FDG PET/CT and whole body MRI, may help find and diagnose extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 77 (estimated)
- First submitted
- 11 Mar 2015
- Start date
- Jul 2020
- Primary completion date
- Sept 2027
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT02390635
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 77
- From Jul 2020 to the primary completion date, Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a known allergy to MR contrast agents
- Patients with uncontrolled diabetes
Lab values
- Estimated glomerular filtration rate (eGFR \<30) will be excluded
Age
- Younger than 18 years
Other
- Patients with contraindications to MR
- Uncontrollable claustrophobia
- Recipients of more than minimal anti-leukemia treatment, with minimal treatment defined as: leukapheresis, hydroxyurea, or Cytarabine more than 1 g per square meter.
- Patients with secondary or relapsed AML or APL should be excluded.
- Patients with known extramedullary leukemia
- Positive pregnancy test in a female of childbearing potential
- Greater than 400 pounds in weight
- Cognitive impaired adults or prisoners will be excluded
Who the study is looking for
- Patients with newly diagnosed AML
- Non-English speaking subjects will be included. Verbal Translation Preparative Sheet (VTPS) short form will be utilized in consenting non-English speaking subjects.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.